Brainsway Ltd
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Hadar Levy
- Full Time Employees
- 129
- Sector
- Health technology
- Industry
- Medical specialties
- Address
- 16 Hartum St Jerusalem JM Israel 9777516
- IPO Date
- Dec 24, 2006
- Website
- brainsway.com
- Similar Companies
- Business
- BrainsWay Ltd. (NASDAQ & TASE: BWAY.TA), founded in 2003 and headquartered in Jerusalem, Israel, with principal U.S. operations in Burlington, Massachusetts, develops and markets noninvasive neurostimulation treatments utilizing its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology for mental health disorders. The company offers FDA-cleared Deep TMS systems for major depressive disorder including anxious depression and late-life depression in patients aged 15 to 86, obsessive-compulsive disorder as the first de novo noninvasive device, and short-term smoking addiction cessation as the inaugural TMS clearance in the addiction category; it targets treatment-resistant patients and operates through over 800 providers in the United States, East Asia, and internationally. BrainsWay pursues ongoing clinical trials in additional psychiatric, neurological, and addiction indications while maintaining dual listings on NASDAQ and the Tel Aviv Stock Exchange. In August 2025, the company acquired a minority stake in Axis Integrated Mental Health for up to $3.3 million through strategic equity financing to support provider growth and Deep TMS adoption, following a prior $5 million convertible loan to Neurolief Ltd. for potential acquisition of complementary neuromodulation technology; these moves align with a late-2024 initiative for minority investments in U.S. mental health providers amid 26% year-over-year Q2 2025 revenue growth to $12.6 million.
Company News
BrainsWay Announces Strategic Collaboration with Inland Psychiatry Medical Group
BrainsWay Reports Rise in Favorable Accelerated Deep TMS™ Coverage to Over 70 Million Covered Lives
HWG Holdings LP Buys New Stake in Brainsway Ltd. Sponsored ADR $BWAY
Head to Head Survey: CapsoVision (NASDAQ:CV) vs. Brainsway (NASDAQ:BWAY)
Brainsway (NASDAQ:BWAY) Shares Gap Down – What’s Next?
BrainsWay Reports Promising Pilot Study Results in Patients with Depression and Comorbid Early-Stage Alzheimer's Disease Treated with Deep TMS™
Analyzing Brainsway (NASDAQ:BWAY) and Green Thumb Industries (OTCMKTS:GTBIF)
Wall Street Analysts See a 30.07% Upside in Brainsway (BWAY): Can the Stock Really Move This High?
Brainsway (BWAY) Upgraded to Buy: Here's Why
Brainsway Ltd. Sponsored ADR (NASDAQ:BWAY) Receives $16.95 Average Target Price from Brokerages
Brainsway Q2 Earnings Call Highlights
BrainsWay Ltd. (BWAY) Q2 2026 Earnings Call Transcript
BrainsWay Reports Second Quarter 2026 Financial Results and Operational Highlights
BrainsWay: Building A Capital-Light Interventional Psychiatry Ecosystem
Brainsway (NASDAQ:BWAY) Sets New 52-Week High – Here’s What Happened
Brainsway (BWAY) is on the Move, Here's Why the Trend Could be Sustainable
4 Medical Products Stocks Poised to Win Despite Industry Headwinds
BrainsWay Announces Strategic Investment in Radial Health, Inc.
BrainsWay Announces Minority-Stake Investment in Sound Minds Behavioral
Best Momentum Stocks to Buy for July 14th